UPDATE: Qiagen Revenues up 3 Percent in Q2; Plans $100M Stock Buyback | GenomeWeb

The story has been updated to include comments from Qiagen's conference call this morning.

NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Tuesday that revenues for its second quarter increased 3 percent year over year at a constant exchange rate.

The company also announced a new share buyback program of up to $100 million. Based on the closing price of its stock on July 29, that would represent approximately 5 million shares, Qiagen said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.